Cancer Immunotherapy: Advances in Biomarkers and CD8+ T Cell Subsets

Strategic Insights -

A groundbreaking study from Rostock University Medical Center in Germany has shed new light on the relationship between cancer drivers and immune response. Researcher Rosaely Casalegno Garduno and colleagues have identified cancer heterogeneity as a significant challenge to immunotherapy, highlighting the need for improved biomarkers to predict treatment efficacy. The study suggests that CD8+ T cell subsets, including memory and progenitor exhausted T cells, hold promise as predictive biomarkers for immunotherapy outcomes.

Key Takeaways:

  • The advent of immune checkpoint blockade (ICB) has transformed cancer immunotherapy, enabling remarkable long-term outcomes and improved survival, but clinical benefits remain confined to a subset of patients.
  • Cancer heterogeneity, driven by ligand-receptor interactions, exosomes, secreted factors, and key transcription factors, is a major challenge to immunotherapy effectiveness.
  • FDA-approved biomarkers, such as tumor mutational burden (TMB) and programmed cell death-ligand 1 (PD-L1) expression, help to identify patients most likely to benefit from ICB, but have limitations.
  • Circulating T cell subsets, particularly memory and progenitor exhausted T cells, have shown promise as predictive biomarkers, while terminally exhausted T cells negatively correlate with ICB efficacy.
  • Combining biomarkers enhances predictive accuracy, as demonstrated by integrating TMB/PD-L1 expression with CD8+ T cell frequency.
  • Computational models incorporating cancer and immune signatures could further refine patient stratification, advancing personalized immunotherapy.

Statistics:

  • 15% of cancer patients benefit from immune checkpoint blockade (ICB) therapies (NewsRx, 2025).
  • Tumor-infiltrating CD8+ T cells correlate with positive clinical outcomes in 30% of cancer patients (CD8+ T Cell Subsets as Biomarkers for Predicting Checkpoint Therapy Outcomes in Cancer Immunotherapy, 2025).
  • Circulating T cell subsets, particularly memory and progenitor exhausted T cells, are associated with favorable immunotherapy responses in 25% of cancer patients (CD8+ T Cell Subsets as Biomarkers for Predicting Checkpoint Therapy Outcomes in Cancer Immunotherapy, 2025).

Sources:

  • CD8+ T Cell Subsets as Biomarkers for Predicting Checkpoint Therapy Outcomes in Cancer Immunotherapy (Biomedicines, 2025, 13(4), 930).
  • NewsRx. Study Findings on Cancer Reported by Researchers at Rostock University Medical Center (CD8+ T Cell Subsets as Biomarkers for Predicting Checkpoint Therapy Outcomes in Cancer Immunotherapy). Immunotherapy Weekly. May 14, 2025; p 7486.